The natural history of a family with aortic dissection associated with a novel ACTA2 variant.


Journal

Annals of vascular surgery
ISSN: 1615-5947
Titre abrégé: Ann Vasc Surg
Pays: Netherlands
ID NLM: 8703941

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 05 02 2021
revised: 06 04 2021
accepted: 04 05 2021
pubmed: 27 8 2021
medline: 22 2 2022
entrez: 26 8 2021
Statut: ppublish

Résumé

Disease-causing heterozygous variants in the ACTA2 gene cause an autosomal dominant heritable thoracic aortic disease (HTAD) with thoracic aortic aneurysm and dissection as main phenotype, and occasional extravascular abnormalities such as livedo reticularis. ACTA2-HTAD accounts for an important part of non-syndromic HTAD, with detection rates varying between 1.5-21% according to different studies. A consensus statement for the screening and management of patients with pathogenic ACTA2 variants has been recently published by the European reference network for rare vascular diseases (VASCERN). However, management of ACTA2 patients is often challenged by extremely variable inter- and intra-familial clinical courses of the disease. Here we report a family harboring a disease-causing ACTA2 variant. The proband and two siblings presented with acute type A aortic dissection and rupture involving nondilated aortic segments before the age of 30. Their mother died at 49 years-old from type B aortic dissection and rupture. Genetic testing revealed the heterozygous novel p.(Pro335Arg) variant in the ACTA2 gene in the proband and in the affected siblings. The clinical history of this family highlights the difficulty of adopting effective prevention strategies in ACTA2 patients.

Identifiants

pubmed: 34437965
pii: S0890-5096(21)00512-4
doi: 10.1016/j.avsg.2021.05.034
pii:
doi:

Substances chimiques

ACTA2 protein, human 0
Actins 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

348.e7-348.e11

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Pascal Delsart (P)

Institut coeur Poumon, CHU Lille, Lille, France. Electronic address: Pascal.DELSART@chru-Lille.fr.

Clémence Vanlerberghe (C)

Clinique de génétique clinique, CHU Lille, Lille, France.

Francis Juthier (F)

Institut coeur Poumon, CHU Lille, Lille, France; University of Lille, CHU Lille, Lille, France.

Jonathan Sobocinski (J)

Institut coeur Poumon, CHU Lille, Lille, France; University of Lille, CHU Lille, Lille, France.

Olivia Domanski (O)

Institut coeur Poumon, CHU Lille, Lille, France.

Benjamin Longere (B)

Institut coeur Poumon, CHU Lille, Lille, France.

Nadine Hanna (N)

Département de Génétique, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France; Laboratory for Vascular Translational Science, INSERM U1148, Université Paris de Paris, Hôpital Bichat, Paris, France.

Pauline Arnaud (P)

Département de Génétique, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France; Laboratory for Vascular Translational Science, INSERM U1148, Université Paris de Paris, Hôpital Bichat, Paris, France.

Luisa Marsili (L)

Clinique de génétique clinique, CHU Lille, Lille, France; University of Lille, CHU Lille, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH